T1	Participants 121 173	patients with senile dementia of the Alzheimer type.
T2	Participants 924 1008	A total of 204 patients with probable Alzheimer's disease were included in the study
T3	Participants 1020 1214	136 patients were eligible for the according-to-protocol analysis of efficacy, 167 subjects for the intention-to-treat analysis of efficacy, and 181 patients were included in the safety analysis
